Click on a filter below to refine your search. Remove a filter to broaden your search.
Pfizer has reported that its vaccine would reduce risk from RSV by as much as 86%.
An increased concern about migraine worsening was a risk factor for perceived migraine worsening.
Most of the cases of monkeypox occurring following single dose of the MVA-BN vaccine occur within 14 days.
Additional protection against symptomatic infection was provided for people who previously had received monovalent vaccine doses.
Odds ratio of 6.30 for Guillain-Barré syndrome association with SARS-CoV-2 infection and 0.41 for COVID-19 vaccine administration.
COVID-19 vaccination with any number of doses before infection was linked to a reduced risk for post-COVID-19 condition.
Cases are rising in the United States and globally due to pockets of unvaccinated people.
Arexvy was ~82% effective in preventing RSV-induced lower respiratory tract infections in adults aged 60 or more years.
Vaccine effectiveness was 49% at 60 to 119 days after vaccination among tests exhibiting spike gene target failure.
A reduced risk was seen for venous thromboembolism, arterial thrombosis/thromboembolism and heart failure.